-$0.74 EPS Expected for Krystal Biotech, Inc. (NASDAQ:KRYS) This Quarter

Equities research analysts expect Krystal Biotech, Inc. (NASDAQ:KRYS) to report ($0.74) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Krystal Biotech’s earnings. The highest EPS estimate is ($0.69) and the lowest is ($0.80). Krystal Biotech posted earnings of ($0.37) per share during the same quarter last year, which would indicate a negative year over year growth rate of 100%. The firm is scheduled to issue its next earnings results on Monday, August 9th.

On average, analysts expect that Krystal Biotech will report full year earnings of ($2.94) per share for the current year, with EPS estimates ranging from ($3.41) to ($2.68). For the next financial year, analysts anticipate that the business will report earnings of ($3.45) per share, with EPS estimates ranging from ($3.76) to ($2.96). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Krystal Biotech.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Sunday, May 9th. The company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.12).

A number of research analysts have commented on KRYS shares. Zacks Investment Research cut shares of Krystal Biotech from a “hold” rating to a “sell” rating in a research note on Friday, May 14th. HC Wainwright raised their target price on Krystal Biotech from $84.00 to $103.00 and gave the stock a “buy” rating in a research report on Monday, March 1st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $101.40.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Baker BROS. Advisors LP raised its position in Krystal Biotech by 8.8% in the 1st quarter. Baker BROS. Advisors LP now owns 760,412 shares of the company’s stock valued at $58,582,000 after purchasing an additional 61,538 shares during the last quarter. Morgan Stanley raised its position in Krystal Biotech by 6.0% in the 1st quarter. Morgan Stanley now owns 11,706 shares of the company’s stock valued at $901,000 after purchasing an additional 665 shares during the last quarter. Redmile Group LLC raised its position in Krystal Biotech by 23.0% in the 1st quarter. Redmile Group LLC now owns 2,060,132 shares of the company’s stock valued at $158,713,000 after purchasing an additional 385,096 shares during the last quarter. California State Teachers Retirement System raised its position in Krystal Biotech by 11.1% in the 1st quarter. California State Teachers Retirement System now owns 22,732 shares of the company’s stock valued at $1,751,000 after purchasing an additional 2,270 shares during the last quarter. Finally, Great West Life Assurance Co. Can raised its position in Krystal Biotech by 64.8% in the 1st quarter. Great West Life Assurance Co. Can now owns 1,005 shares of the company’s stock valued at $77,000 after purchasing an additional 395 shares during the last quarter. Hedge funds and other institutional investors own 74.29% of the company’s stock.

Shares of KRYS opened at $67.30 on Tuesday. The company’s 50-day moving average is $68.96. Krystal Biotech has a 52 week low of $37.68 and a 52 week high of $87.29.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.

Read More: Percentage Gainers

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.